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Abstract
At high internal doses, pharmaceuticals have the potential for inducing biological/pharmaco-
logical effects in fish. One particular concern for the environment is their potential to bioaccu-
mulate and reach pharmacological levels; the study of these implications for environmental
risk assessment has therefore gained increasing attention. To avoid unnecessary testing on
animals, in vitro methods for assessment of xenobiotic metabolism could aid in the ecotoxi-
cological evaluation. Here we report the use of a 3-D in vitro liver organoid culture system
(spheroids) derived from rainbow trout to measure the metabolism of seven pharmaceuti-
cals using a substrate depletion assay. Of the pharmaceuticals tested, propranolol, diclofe-
nac and phenylbutazone were metabolised by trout liver spheroids; atenolol, metoprolol,
diazepam and carbamazepine were not. Substrate depletion kinetics data was used to esti-
mate intrinsic hepatic clearance by this spheroid model, which was similar for diclofenac
and approximately 5 fold higher for propranolol when compared to trout liver microsomal
fraction (S9) data. These results suggest that liver spheroids could be used as a relevant
and metabolically competent in vitro model with which to measure the biotransformation of
pharmaceuticals in fish; and propranolol acts as a reproducible positive control.
Introduction
The study of pharmaceuticals and personal care products (PPCPs) in the environment has
prompted significant attention due to their potential for inducing both short and long-term
biological effects in aquatic organisms [1]. As these compounds are designed to act on specific
therapeutic targets (e.g. enzymes, transporters and receptors) in humans [2], that are often
conserved across vertebrate phyla, it is possible that inducible effects demonstrated in human
target systems may also induce similar effects in non-target organisms, such as fish [3, 4].
Additionally, the continued presence of these contaminants in the aquatic environment gives
rise to the potential risk of accumulation in fish and other aquatic organisms [5–7], although
as yet not clearly established outside the laboratory. Since the adoption of the United Nations
Stockholm Convention on persistent organic pollutants (POPs) in 2001, there has been
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significant activity concerning the assessment of the number of persistent, bioaccumulative
and toxic (PBT) substances worldwide [8]. In addition, there have been extensive calls from
regulations such as REACH (Registration, Evaluation and Authorisation of Chemicals) to
avoid unnecessary testing of these substances on animals in line with commitments to and
support of the 3Rs (Replacement, Reduction, Refinement) initiatives. Instead to utilise existing
information from standard and non-standard methods, in vitro methods, read-across and
weight-of-evidence approaches, in an integrated testing strategy for assessing the PBT nature
of these substances [9, 10].
Conventional alternative bioaccumulation assessments for fish rely mainly on in silico
approaches such as Quantitative Structure Activity Relationships (QSAR) that relate molecular
properties of a compound to a measure of a particular activity (i.e. acute toxicity) [8]; perhaps
due to the cost and labour intensity of performing large-scale in vivo bioaccumulation tests
[11]. Unfortunately, these computational predictions are not validated for many chemical clas-
ses, including pharmaceuticals, and more importantly they do not account for the impact of
metabolism in the organism [12]. In fact, these estimates of bioaccumulation can be signifi-
cantly affected by an organism’s ability to metabolise a chemical [13, 14]. It is assumed that
metabolism (biotransformation) of a xenobiotic is likely to result in improved clearance. In
recent years, the use of in vitro techniques in the bioaccumulation assessment of PPCPs has
received more attention, with a particular focus on the measurement of metabolism and the
extrapolation of this data to an in vivo scale, to aid improved predictions of the bioconcentra-
tion potential of these chemicals [15]. In particular, the use of three-dimensional (3-D) hepatic
fish cultures or ‘spheroids’ has been proposed as an alternative model with which to assess
metabolism, efflux and bioaccumulation potential of PPCPs in aquatic environments due to
their in vivo-like physiology [10, 16–18].
As in vitro studies with fish hepatic models can be used to support screening-level bioaccu-
mulation assessment of contaminants [2, 13, 14, 19], the aims of the present study were as fol-
lows: (1) determine the metabolic competency of 3-D liver spheroids prepared from rainbow
trout, a recommended regulatory fish species, towards selected environmentally relevant phar-
maceuticals; (2) utilise this in vitro data to (a) make predictions on pharmaceutical metabolism
in fish based on ‘read-across’ to human metabolism data and (b) calculate intrinsic clearance




This in vitro model of fish liver spheroids utilises primary liver cells derived from freshly killed
rainbow trout, Oncorhynchus mykiss (Walbaum), supplied from the fish husbandry facility of
the AstraZeneca Brixham Environmental Laboratory. The fish were held with permission
from the UK Home Office within compliance with the AstraZeneca Global Ethics Policy. Prior
to cell harvest, the fish were killed humanely under Schedule 1 of the Animals (Scientific Pro-
cedures) Act 1986. Since the fish were not exposed to any test compounds, and that individual
animals were used to test multiple substances, we believe this work contributes to replacement
and reduction of animals compared to standard methods of in vivo exposure.
Pharmaceuticals, chemicals and reagents
Atenolol (purity98%; CAS 29122-68-7), metoprolol succinate (purity98%; CAS 98418-
47-4) and propranolol hydrochloride (purity 99%; CAS 318-98-9) were obtained from
AstraZeneca (Alderley Park, UK). Diclofenac sodium salt (purity98%; CAS 15307-79-6),
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phenylbutazone (purity98%; CAS 50-33-9), carbamazepine (purity98%, CAS 298-46-4)
and diazepam (purity98%; CAS 439-14-5) were purchased from Sigma-Aldrich (Poole,
UK). All chemicals and reagents for tissue culture procedures were obtained from Life Tech-
nologies Ltd (Paisley, UK). Pharmaceuticals were prepared fresh on the day of exposure in sol-
vent (DMSO) and diluted in Leibovitz’s L-15 medium (no serum or antibiotic addition) to a
concentration of 200 μg L-1 (0.2% DMSO). A final well concentration of 100 μg L-1 (0.1%
DMSO) for each pharmaceutical was used. Pharmaceuticals that carried a salt weight were
accounted for when calculating exposure concentrations i.e. final well concentrations refer to
parent chemical minus the counter ion.
3-D liver spheroid culture
Maintenance of female diploid rainbow trout [Oncorhynchus mykiss (Walbaum)] (wet weight:
116.0 ± 21.7 g) and liver dissociation procedures are described previously [10]. Individual liv-
ers (wet weight: 1.43 ± 0.34 g) produced a sufficient cellular yield to use single fish replicates,
thus each fish was used as an individual experiment. Cell viability after isolation was determined
by a trypan blue exclusion test (0.2% final volume; L-15 medium) and cell suspensions with a
viability of 85% were used for spheroid culture. Penicillin-Streptomycin (5,000 U mL-1) and
amphotericin B (250 μg mL-1) were added to the culture medium (1% v:v) in addition to foetal
bovine serum (FBS; 10% v:v). Cell suspension aliquots (1 X 106 cells mL-1; 3 mL volume) were
transferred to wells of Poly(2-hydroxyethyl methacrylate) (pHEMA)-coated six-well micro-
plates (Falcon, VWR, UK) and placed on an orbital shaking platform (Innova 2000, Eppendorf,
UK), set at a constant rotation speed of 70 RPM. Plates were maintained at 15 ± 1˚C in a tem-
perature controlled laboratory. Culture media was replaced every two days until spheroids
reached maturity (8 days). A more detailed protocol for cell isolation and spheroid formation
is described previously [10].
Preparation of spheroids for exposures
Spheroids (8 d) were pooled (for each individual fish liver) from 6-well micro plates, into a
pHEMA-coated 50 mL centrifuge tube and washed three times with 10 mL L-15 medium (no
serum or anti-biotic mixture; spheroids were allowed to sediment without centrifugation prior
to each washing step). As spheroids are too large to be counted on a haemocytometer, 4 x 5 μL
drops of spheroid suspension were transferred to a glass microscope slide and spheroids were
counted at x4 magnification under an inverted light microscope (Olympus1 CK40-SLP).
Spheroid suspensions were transferred to a sterile reagent reservoir, agitated with a multi-
channel pipette to maintain a homogenous suspension and transferred to 96-well pHEMA-
coated micro plates (Iwaki, Sterilin, UK) at a seeding density of 100 spheroids well-1 (in 75 μL
L-15 medium; pH 7.4). Morphological integrity of spheroids was assessed and disaggregated
or fused spheroids removed as a quality control check.
Tetrazolium salt reduction (WST-1) viability assay
Spheroid viability was determined prior to substrate depletion experiments by a tetrazolium
salt reduction method (WST-1 reagent, Roche Scientific, UK). Final well test concentrations of
each pharmaceutical were 0, 32, 100 and 320 μg L-1; 0.1% DMSO; n = 6 wells per concentra-
tion). A solvent control (1% Triton X-100; 0.1% DMSO) was also included in the assay (n = 6
wells), as was a positive control (propranolol 100 μg L-1). Plates were incubated at 15˚C for
48 h. After 24 h of exposure, 15 μL of WST-1 reagent was added directly to each well (1:10 dilu-
tion) and plates incubated for a further 24 h. Absorbance was read in a micro-plate reader
(SpectraMax M5, Molecular Devices, USA) at 450 nm.
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Substrate depletion assay
Spheroids prepared from two separate livers were exposed in parallel on separate micro plates. To
each row of a 96-well micro plate the following was added in 75 μL aliquots: (a) exposure medium
(spheroids + media & pharmaceuticals; n = 6 wells); (b) solvent control medium (spheroids +
media & solvent; n = 3 wells) and (c) exposure medium controls (pharmaceuticals—spheroids;
n = 3 wells). Each micro plate row was allocated a time-point (0, 0.5, 1, 2, 4, 24 h; n = 12 wells)
and substrate depletion quenched with the addition of 150 μL acetonitrile (ACN) at each respec-
tive time-point (in the instance where substrate depletion was not measured after 24 h, exposures
were continued to72 h). Plates were sealed to eliminate evaporative losses and analysed for sub-
strate depletion by liquid chromatography with tandem mass spectrometry (LC-MS/MS). All
assays were performed at a physiologically relevant temperature for rainbow trout (15˚C ± 1˚C).
In summary, compounds were tested individually against spheroids generated from at least two
individual fish livers, and chemical analysis conducted on samples from at least six time points.
LC-MS/MS analysis
Standard solutions were prepared for each pharmaceutical to cover the range 1 to 1000 nM.
These were made up to match the sample solvent composition i.e. 80:20 water:ACN containing
10 nM internal standard. Analyses were performed using a TSQ Quantum Access mass spec-
trometer (Thermo Scientific, San Jose CA, USA). Chromatographic separation was achieved by
gradient elution on a Hypersil Gold 2.1 x 50 mm 3 μm C18 column (Thermo Scientific, San Jose
CA, USA). The mobile phase was a mixture of (A) 0.1% formic acid in water and (B) 0.1% for-
mic acid in methanol programmed as follows: 80% A to 100% B over 1.5 min and held for 1.5
min, then reset to initial conditions. The flow rate was 500 μL min-1 with an injection volume of
20 μL. The mass spectrometer was operated in electrospray ionization mode using selected ion
monitoring with a capillary temperature of 270˚C, vaporiser temperature 350˚C, spray voltage
3750 V, sheath gas nitrogen @ 50 (arbitrary units) and auxiliary gas nitrogen at 30 (arbitrary
units). Each compound was automatically optimized for ion polarity, precursor ion, and prod-
uct ion and collision energy using QuickQuan software (Thermo Scientific San Jose CA USA).
Data analysis
The depletion of parent substrate from the culture medium was determined by plotting mea-
sured concentration of test chemical (μg L-1) vs. incubation time (h-1). The depletion rate con-
stant (k; h-1) was calculated by non-linear regression analysis (Sigma Plot 12.5, Systat Software,
San Jose, USA), using a two parameter, exponential decay equation (y = ae-bx). The half-life (t1/2)
for the exponential decay of the parent substrate was calculated using the depletion rate constant
(t1/2 = (ln2)/k). Rate constants were divided by total cell number which approximated to 50,000
cells well-1—based on approx. 500 cells spheroid-1 and 100 spheroids well-1, (we have previously
measured variability [10]) to calculate in vitro intrinsic clearance (ClINT, IN VITRO mL h-1 cell-1;
adapted from [2, 14]). This data was then extrapolated to calculate intrinsic hepatic clearance
(ClINT, HEPATIC mL h
-1 g liver-1) to facilitate direct comparison with human data in the literature.
For viability assays, datasets were analysed using one-way ANOVA with post-hoc Tukey HSD
test (Minitab v15, Minitab Inc, USA).
Results and Discussion
Pharmaceutical metabolism
Pharmaceuticals representing four different drug families were chosen based on (a) their
reported presence in the aquatic environment [6] and/or (b) biotransformation and
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bioaccumulation criteria taken from published human, mammalian and fish literature (see
Tables 1, 2 & 3). A description of the pharmaceuticals and substrate depletion data is shown in
Table 1. Substrate depletion kinetics and depletion rate constants for each pharmaceutical
were determined using exponential decay curve-fit analysis (non-linear regression; Fig 1). Sub-
strate depletion kinetics in spheroid cultures do not appear to be strictly linear, therefore we
utilised a non-linear regression to calculate depletion constants. Propranolol metabolism was
measured in multiple substrate depletion experiments (% loss: 41 ± 15.8; n = 12 fish) (Table 4).
In comparison, the β-blockers atenolol (n = 4 fish) and metoprolol (n = 4 fish) demonstrated
no evidence of substrate depletion in the 24 h exposure period, which was further examined at
extended time points48 h (atenolol) and72 h (metoprolol). Propranolol was metabolised
by spheroids from these individual fish run concurrently as a positive control for all com-
pounds. Besides the current study and two others [2, 20], little is currently published on the
metabolism of β-blockers in fish, therefore, we have little choice but to rely on extrapolated
Table 1. Pharmaceuticals used in substrate depletion experiments using trout liver spheroids. Substrate decrease over total incubation period (%),
depletion rates constant (k; h-1) and half-life (t1/2) values are shown as mean ± SD. NSD = no substrate depletion.
Pharmaceutical Category Log Kow (pH) % decrease over total Depletion rate Half-life hours (t1/2)
incubation period constant (k; h-1)
Atenolol Selective 0.02 (7.4) NSD - -
beta blocker
Carbamazepine Anticonvulsant 2.47 (7.0) NSD - -
Diazepam Benzodiazepine 2.70 (7.0) NSD - -
anxiolytic
Diclofenac sodium NSAID 4.02 (7.0) 39.3 ± 12.0 0.021 ± 0.008 39.2 ± 22.4
salt
Metoprolol Selective 0.09 (7.4) NSD - -
succinate beta blocker
Phenylbutazone NSAID 3.16 (7.4) 34.4 ± 12.9 0.015 ± 0.006 51.0 ± 22.9
Propranolol HCl Non-selective 0.72 (7.0) 41 ± 15.8 0.022 ± 0.010 39.4 ± 23.9
beta blocker
doi:10.1371/journal.pone.0168837.t001
Table 2. Prediction of pharmaceutical metabolism in trout liver spheroids based on ‘read-across’ from human metabolism data. † Pharmaceuticals
are ranked according to the Biopharmaceutics Drug Disposition Classification System (BDDCS) [23] where 1 = High solubility / extensive metabolism; 2 = Low
solubility / extensive metabolism; 3 = High solubility / poor metabolism. + Major CYP enzymes believed responsible for the metabolim of pharmaceuticals in
humans (modified from [2] with additional data sourced from [44–47].
Parent Classification † %
metabolised
Major CYP enzyme Metabolism Predicted
in humans † in humans + Humans Trout
(spheroids)
Atenolol 3 6.00 2D6 X X ✔
Carbamazepine 2 99.50 3A4 ✔ X X
Diazepam 1 99.50 2C19 / 3A4 ✔ X X
Diclofenac sodium
salt
1 99.50 Believed to be principly 2C and likely 2C9. Several minor





1 99.00 2D6 ✔ X X
Phenylbutazone 1 99.00 Likely 2D6, 2C19, 3A4 ✔ ✔ ✔
Propranolol HCl 1 99.75 1A2 / 2D6 ✔ ✔ ✔
doi:10.1371/journal.pone.0168837.t002
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metabolism / pharmacokinetic data from mammalian studies to aid in our prediction of bio-
transformation and clearance of pharmaceuticals in fish [4]. Although their chemical struc-
tures share a number of similarities, the variation around the aromatic ring leads to a number
of pharmacokinetic differences between different β-blockers. These include rate of uptake,
lipid solubility, degree and rate of first-pass metabolism in the liver, binding to plasma pro-
teins, half-life, and renal clearance of the drug and/or its metabolites [21, 22].
In mammals, relatively more hydrophobic β-blockers such as propranolol and metoprolol
undergo extensive Phase I hepatic metabolism with ~90% of the parent excreted by the kidneys
as metabolites in the urine [23, 24]. Hydrophilic atenolol does not undergo such extensive
Table 3. Comparison of intrinsic hepatic clearance rates (CLINT, HEPATIC) of propranolol and diclofenac by trout liver spheroids with trout, human
S9 and human hepatocytes. Clearance rates for human S9 and hepatocytes are shown as mean ± SD and taken from studies reviewed previously [2].
Clearance rates for trout S9 are taken from two previous fish in vitro studies [2,20]. Where no SD is provided, the data are collated from multiple studies and
the figures provided for an indication of comparable rates.
Pharmaceutical CLINT, HEPATIC (intrinsic hepatic clearance: mL h-1 g liver-1)
Trout S9 Trout spheroid Human S9 Human hepatocyte
Propranolol HCl 78.5 ± 82.7 54.0 52.5 ± 19.1 82.2 ± 39.9
Diclofenac sodium 9.5 49.8 368.0 ± 201.4 256.8 ± 123.1
salt
doi:10.1371/journal.pone.0168837.t003
Fig 1. Substrate depletion kinetics of propranolol by trout liver spheroid cultures prepared from two
separate fish livers. Closed circles denote cultures from fish one; open circles denote cultures from fish two (n = 6
at each time point). Values at each time point are mean ± SE. Substrate depletion kinetics determined using two-
parameter, exponential decay curve-fit analysis (non-linear regression; Sigma Plot v12.5, Systat Software, San
Jose, USA).
doi:10.1371/journal.pone.0168837.g001
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metabolism and is excreted predominantly as the parent compound [25] with typically 94%
excreted unchanged in human urine [24]. It is therefore of little surprise that the spheroids
appear not to metabolise atenolol in this study. In humans, similar to propranolol, metoprolol
is metabolised and eliminated by several oxidation pathways, the major of which via O-deme-
thylation and further oxidation to a carboxylic acid metabolite that in man accounts for ~65%
of the dose [26]. Metabolism of propranolol is affected by genetic polymorphism for both
CYP1A (mephenytoin hydroxylation) and CYP2D6 (debrisoquine hydroxylation) isozymes in
the liver [27, 28]. Metoprolol metabolism in particular is significantly affected by debrisoquine
hydroxylation polymorphism [27]. Previous genomic studies with both rainbow trout [29] and
zebrafish [30] has demonstrated an absence of CYP2D6, which could explain the lack of meto-
prolol metabolism demonstrated here; however the metabolism of propranolol and diclofenac
might suggest the presence of another enzyme with similar function (Table 2).
Variability of substrate metabolism between individual fish (Table 2) is inevitably as a
result of inherent metabolic differences, particularly in terms of their physiology and genetic
makeup, which could be driving different pathways to the metabolism of propranolol i.e. mod-
ulation between the three major pathways [31]. Potential differences in the viability and mor-
phological integrity of spheroids could contribute to this variation in metabolism; however,
morphological integrity was rigorously assessed prior to exposure as a quality assurance check.
There was no effect of any of the pharmaceuticals on spheroid viability ( 320 μg L-1), mea-
sured using a tetrazolium salt reduction assay, in any of the repeated exposures. Our choice of
single fish replicates in this experiment was to assess the importance of the differences between
individual animals and possible differences within each culture batch over time that might
potentially affect the rate of xenobiotic metabolism [18, 31]. We suggest this is likely to reflect
differences among fish in vivo and could contribute to the five-fold measured variability in cir-
culating propranolol concentrations already reported in trout [32]. Given our understanding
of the variability between individuals for propranolol, and balancing this against the numbers
of fish required, we suggest two fish (biological replicates) are likely to be appropriate for
investigative studies.
Table 4. Propranolol depletion over time (%) measured over 24h incubation, calculated depletion rate constants (k; h-1) and half-life (hours) (t1/2)
for liver spheroid cultures from individual fish experiments. Values for each individual fish experiment are mean ± sd from combined spheroid cultures
(n = 6 wells). Initial measured dose at time zero was 98 ± 4 μg/L (n = 72 wells). Individual differences between fish were analysed by the natural log transform
of the % depletion (normally distributed) and a one-way anova with Tukey post hoc to identify individual fish (fish sharing the same letter A through D are not
different to one another). Fish number 12 had significantly slower clearance than any other fish (p<0.001), but has not been excluded from the dataset.
Individual fish
experiment
Propranolol depletion over 24h incubation







1 24 ± 5 0.010 70.0 D
2 36 ± 9 0.017 40.3 C,D
3 39 ± 10 0.020 34.1 B,C
4 68 ± 11 0.045 15.5 A
5 39 ± 5 0.019 36.5 B,C
6 51 ± 12 0.027 25.7 A,B,C
7 34 ± 4 0.018 39.6 C,D
8 56 ± 5 0.032 21.6 A,B
9 34 ± 4 0.017 41.0 C,D
10 52 ± 6 0.029 23.7 A,B,C
11 50 ± 7 0.029 24.0 A,B,C
12 15 ± 5 0.007 100.4 E
Mean ± SD 41 ± 15.8 0.022 ± 0.010 39.4 ± 23.8
doi:10.1371/journal.pone.0168837.t004
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The degree of substrate depletion was similar in both non-steroidal anti-inflammatory
drugs (NSAID) diclofenac (% loss: 39.3 ± 12.0; n = 4 fish) and phenylbutazone (% loss:
34.4 ± 12.9 n = 3 fish). Metabolism of diclofenac has been demonstrated previously in vitro
with rainbow trout liver microsomal fractions (S9) [2]. Both larval zebrafish (Danio rerio) [33]
and juvenile rainbow trout [34, 35] have demonstrated diclofenac metabolism in vivo with
measurable levels of phase I and II metabolites. Metabolites and un-metabolised diclofenac
have also been detected in the bile of adult rainbow trout [36], although large variations in
both up-take and metabolism were observed between individual animals. Like propranolol,
diclofenac is substrate for more than one human CYP, including CYP1A2 and 2D6 [2]. Phen-
ylbutazone has demonstrated extensive metabolism in both humans [37] and horses [38] pre-
viously, but we are aware of no studies except the current on fish. Little seems to be known
about exactly which cytochrome enzymes are involved in metabolism of phenylbutazone, but
it seems likely that 2D6, 2C19, 3A4 are the primary enzymes in man; phenylbutazone is a well-
documented strong inhibitor of human liver microsomal CYP2C9 activity [39].
No substrate depletion of the anticonvulsant carbamazepine, or the benzodiazepine anxio-
lytic diazepam was measured in any experiments. No measurable metabolism of carbamaze-
pine in fish liver S9 fractions, a substrate for CYP3A4 in humans, has also been reported
recently [2]. These authors also suggest that differences in CYP3A specificity between trout
and mammals could lead to an absence of CYP3A4-like activity in trout, and that trout and
other fish species may metabolise some, but not all, mammalian CYP3A substrates (but see
phenylbutazone above), instead utilizing enzymes from other CYP families (e.g. CYP1A).
CYP3A4 has not been identified in rainbow trout previously [29]. Several studies have demon-
strated the involvement of CYP2C and CYP3A sub-families in human liver microsomal diaze-
pam metabolism, with 3-hydroxylation catalyzed primarily by 3A P450s and N-demethylation
partially mediated by 2C P450s [40–42].
The approach of studying the metabolism of pharmaceuticals in aquatic organisms via the
“read-across” of mammalian toxicity and detoxification systems is important when such little
data exists on these systems in fish [3, 4, 21, 31, 43, 44]. With reference to published pharma-
ceutical metabolism data from humans and fish (both in vivo and in vitro) and with particular
reference to the substrate / CYP relationship (Table 2), data acquired from this and from previ-
ous in vitro fish metabolism studies, highlights the degree of caution that must be taken when
presuming a homology of metabolic pathways between aquatic and terrestrial species [2].
Given the species differences and physiological / environmental factors such as temperature,
direct comparisons of biotransformation and kinetics remain to be further investigated. Of the
seven pharmaceuticals tested, four (propranolol, diclofenac, phenylbutazone and atenolol)
demonstrated predicted substrate depletion based on read-across to human metabolism data
[2, 45–48].
The enzyme CYP1A2 acts on both propranolol and diclofenac as its major and minor sub-
strate respectively, with the latter having several CYP enzymes implicated in its metabolism
[CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4] in humans [2]. Trout liver
spheroids exhibited a lack of activity towards the major CYP2C9 substrate (metoprolol), as
well as major CYP2C19 and CYP3A4 substrates (diazepam and carbamazepine respectively),
suggesting that fish may lack these isoforms (particularly in vitro) as demonstrated previously
in rainbow trout [29] and zebrafish [30]. Further, in vitro systems may require pre-incubation
with known CYP-inducers in order to up-regulate biotransformation systems in order to
quantify metabolism in these substrates. For instance, incubation of fluoxetine with fish liver
microsomal fractions obtained from several fish species, including rainbow trout, demon-
strates slow, variable and often undetectable metabolism [2, 49], unless fish are pre-exposed to
the major CYP3A4 substrate carbamazepine [49]. Therefore, we propose that propranolol may
Trout Spheroids Metabolise Pharmaceuticals
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be another suitable candidate CYP-inducer in co-exposure studies where CYP 1A and 2D
pathways might be predicted, and co-exposure a possibly more ecologically relevant approach.
Identification of CYP enzymes and / or similar isoforms warrants further investigation to
determine the specific metabolic pathways responsible for pharmaceutical biotransformation
in fish. As the rainbow trout genome has now been sequenced [50], identification of these
CYP enzymes and isoforms may now be possible.
In line with established and current extrapolation protocols for in vitro fish metabolism
models [2, 12–14, 19, 51–54], we calculated clearance rates for propranolol and diclofenac and
compared them with human clearance rates derived from the literature (Table 3; modified
from trout and human intrinsic hepatic clearance literature review [2]). The extrapolation fac-
tors of 120 x 106 hepatocytes g liver-1 and 50 mg microsomal protein g liver-1 used previously
to convert literature values from human studies to mL h-1 g liver-1 [55, 56], for comparison to
calculated trout clearance rates [2] were adopted in this study. The extrapolation factor for
hepatocyte number was normalised against that obtained from spheroid experiments (91 x 106
hepatocytes g liver-1). A high degree of variability was observed between rates collected from
trout S9, human S9 and human hepatocyte studies for both drugs [55, 56]. Further, the other
studies on diclofenac metabolism in fish focus on metabolite identification in the bile, making
direct comparisons impossible [35, 36]. However, based on the limited dataset available, and
taking study variability into account, estimated intrinsic hepatic clearance for propranolol in
trout liver spheroids are similar to values recorded for humans previously (Table 3).
The rate for diclofenac was lower, however, a high degree of variability was again observed
in these human studies. Clearance rate for propranolol was ~5 fold higher in trout spheroids
but similar for diclofenac when compared to trout S9 data, although these comparable datasets
are limited. It is unclear at this point whether clearance rates calculated using S9 fractions are
an underestimation when compared to whole tissue. Due to scarcity of comparable data, it is
currently unclear if differences between the various methods and compounds are biologically
meaningful or reproducible. A previous study [2] conducted an intra-laboratory comparison
of fish microsome metabolism and saw both re-assuring similarity but also identified variation.
Here we demonstrate biological variability between individuals and replication reproducibility
for a model we would expect to be more like an in vivo situation
It is also difficult to know exactly the effects of isolating cells and short-term measures com-
pared to long-term 3-D culture techniques on rate values. For trout liver, [16–17], direct com-
parisons of freshly excised tissue; isolated cells in suspension and spheroids in extended
culture demonstrated, with some exceptions, that gene expression and transporters in 3-D
structures approximate well to the excised tissue. This suggests that the model represents at
least some of the aspects of the in vivo situation. Further studies at both in vitro and in vivo
level are urgently required to determine the sensitivity of S9 and tissue models in predicting
whole animal responses with respect to biotransformation. As yet we are in no position to
begin to understand the scale of an appropriate conversion factor for translating in vitro to in
vivo as is common practice in mammalian pharmacology.
This study highlights the importance in understanding the metabolism of target pharma-
ceuticals in the mammal to better understand the pharmacokinetics in fish. In addition to the
data presented here, propranolol demonstrates transport across gill epithelium [22]; uptake
into blood plasma [32]; comparable hepatic biotransformation enzyme activity (EROD) induc-
tion rates under both in vitro and in vivo exposure conditions [31]; measurable substrate deple-
tion in in vitro systems [2, 20] and the present study; and low toxicity in vivo [32] in fish, and
therefore would be suitable as a positive control chemical to investigate metabolism. As a con-
sequence of our experience in these studies, a concentration of 100 μg L-1 and an exposure
period of 24 h are proposed as suitable parameters for subsequent pharmaceutical exposures
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utilising trout liver spheroids. Traditionally, in vitro toxicology experiments often use 24 h
time-points and we utilised this design to demonstrate for the first time the sustained meta-
bolic clearance in 3-D trout spheroids. However from our data, although we demonstrate a
consistent depletion over 24 h, an acute exposure period (4 h) may be sufficient to measure sig-
nificant metabolism of propranolol. Further, we believe the spheroids generated are of appro-
priate size to maintain normoxic conditions [57]. The compromise is that concentrations must
be both pharmacologically relevant and analytically quantifiable in small working volumes.
Concentrations at environmentally relevant levels are rarely quantifiable inside fish and espe-
cially at low volume [4]. The time course of 24 h provides time for acclimation and the poten-
tial for both phase I and II metabolism, giving relevant data for future physiologically based
pharmacokinetic (PBPK) modelling applications.
In addition, with such limited data available on in vivo pharmaceutical metabolism in fish,
we stress the importance, but also caution, of utilising read-across and extrapolation data from
human / mammalian studies to aid predictions of biotransformation and clearance in trout.
Further extrapolation of in vitro data for BCF calculations; an understanding of CYP enzymes
responsible for drug metabolism, and information on biotransformation in other target organs
(particularly those on the route of exposure such as gill or intestine), is an essential research
requirement to enable a more thorough in vitro assessment of the bioaccumulation potential
of pharmaceuticals in fish. Equally, utilization of such laboratory data (both in vivo and in
vitro) for comparison with bioaccumulation endpoints measured in field experiments [58], is
an essential direction for chemical bioaccumulation research in aquatic organisms.
Supporting Information
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